Phibro Animal Health Q3 Sales Up 10% to $383.5M, Beats Profit Estimates
PAHC has more than doubled off its 52-week low of $18.89.
Summary
Phibro Animal Health reported strong fiscal Q3 results, significantly beating analyst expectations across key metrics. Sales rose 10% year-over-year to $383.50 million, surpassing the $367.02 million consensus. Adjusted EPS of $0.76 and Adjusted EBITDA of $60.80 million also exceeded estimates. This performance continues a positive trend, following an outstanding Q2 FY2026, and suggests the company is effectively navigating recent challenges such as insider selling and a Brazilian regulatory ban. The robust growth, driven by strong demand in the Animal Health segment, contributions from a recent acquisition, and improved gross margins, is likely to reinforce investor confidence and support the stock, which is currently trading near its 52-week high. Traders will be watching for sustained growth momentum and any further updates on regulatory environments.
At the time of this announcement, PAHC was trading at $58.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.89 to $60.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.